RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking

Gad, S. A. Abo Elwafa, D. A. Hussein, S. A. Fukano, K. Kato, T. Shoji, I. Chayama, K. Muramatsu, M. Isogawa, M. Wakita, T. Merk, D. Aly, H. H.
Antiviral Res. 2025 Aug;240:106214. doi: 10.1016/j.antiviral.2025.106214.

A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

Rsi Suwardana, G. N. Abe, T. Deng, L. Matsui, C. Okitsu, T. Yamada, T. Hatano, M. Wiriyasermkul, P. Nagamori, S. Gad, S. A. Aly, H. H. Nishitsuji, H. Shimotohno, K. Shoji, I.
Antiviral Res. 2025 Aug 30;243:106267. doi: 10.1016/j.antiviral.2025.106267.

Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice

Duehren, S. Uchida, T. Tsuge, M. Hiraga, N. Uprichard, S. L. Etzion, O. Glenn, J. Koh, C. Heller, T. Cotler, S. J. Oka, S. Chayama, K. Dahari, H.
Virus Res. 2024 Aug 26;349:199451. doi: 10.1016/j.virusres.2024.199451.

Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

Chida, T. Ishida, Y. Morioka, S. Sugahara, G. Han, C. Lam, B. Yamasaki, C. Sugahara, R. Li, M. Tanaka, Y. Liang, T. J. Tateno, C. Saito, T.
JCI Insight. 2023 May 8;8(9):e162404. doi: 10.1172/jci.insight.162404.

Fungal Secondary Metabolite Exophillic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses

Kobayashi, C. Watanabe, Y. Oshima, M. Hirose, T. Yamasaki, M. Iwamoto, M. Iwatsuki, M. Asami, Y. Kuramochi, K. Wakae, K. Aizaki, H. Muramatsu, M. Sureau, C. Sunazuka, T. Watashi, K.
Viruses. 2022 Apr 6;14(4). pii: v14040764. doi: 10.339/v14040764.

Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model

Ye, X. Tateno, C. Thi, E. P. Kakuni, M. Snead, N. M. Ishida, Y. Barnard, T. R. Sofia, M. Shimada, T. Lee, A. C. H.

ACS Infect Dis. 2018 Nov 8. doi: 10.1021/acsinfecdis.8b00192.

A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide

Kaneko, M. Watashi, K. Kamisuki, S. Matsunaga, H. Iwamoto, M. Kawai, F. Ohashi, H. Tsukuda, S. Shimura, S. Suzuki, R. Aizaki, H. Sugiyama, M. Park, S. Y. Ito, T. Ohtani, N. Sugawara, F. Tanaka, Y. Mizokami, M. Sureau, C. Wakita, T.

J Virol. 2015 Dec;89(23):11945-53. doi: 10.1128/JVI.01855-15.